A prospective, randomized, open label, phase III trial of fludarabine, cyclophosphamide [Cytoxan], and rituximab [Rituxan] vs. pentostatin [Nipent], cyclophosphamide, and rituximab in previously untreated or treated B-cell chronic lymphocytic leukemia.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 18 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cyclophosphamide; Fludarabine; Pentostatin; Rituximab
Indications Chronic lymphocytic leukaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

03 Nov 2016 Biomarkers information updated
16 Sep 2011 Results published in the Investigational New Drugs.
08 Dec 2008 Results were presented at ASH in Dec 2008.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight